Table 2 Secondary infection risks (SIR) during contact tracing and chemoprophylaxis against influenza A (H1N1-2009)
Authors | Ages traced | No. subjects traced | Secondary cases with prophylaxis | SIR % (95% CI) with prophylaxis | No. w/o prophylaxis | Secondary cases w/o prophylaxis | SIR % (95% CI) w/o prophylaxis | Secondary case ascertainment |
|---|---|---|---|---|---|---|---|---|
Baz et al. [18] | 15, 18, 50 and 59 y/o | 4 | 1 | 25.0 (0, 67.4) | 0 | 0 | NC | RT-PCR |
Calatayud et al. [19] | N/A | 2042 | 0 | 0 | N/A | N/A | N/A | RT-PCR |
CDC [20] | N/A | 43 | 0 | 0 | N/A | N/A | N/A | ILI |
CDC [20] | N/A | 284 | 6 | 2.1 (0.4, 3.8) | 16 | 0 | 0 | ILI |
CDC [20] | N/A | 983 | 176 | 17.9 (15.5, 20.3) | N/A | N/A | N/A | ILI |
Fallo et al. [21] | N/A | 266 | 29 | 10.9 (7.2, 14.7) | 31 | 12 | 38.7 (21.6, 55.9) | ARI/ILI |
France et al. [22] | Median 45 y/o (range: 0–91 y/o) | 50 | 2 | 4.0 (0, 9.4) | 651 | 76 | 11.7 (9.2, 14.1) | ILI |
Iioka et al. [23] | N/A | 49 | 6 | 12.2 (3.1, 21.4) | 0 | 0 | NC | RDT/RT-PCR |
Jackson et al. [24] | N/A | 9.7†| 3.6†| 37.1 (6.7, 67.5) | 69.3†| 11.5†| 16.6 (7.8, 25.4) | Serology |
Komiya et al. [6] | Median 43 y/o (quartiles: 0–82) | 333 | 2 | 0.6 (0, 1.4) | 46 | 12 | 26.1 (13.4, 38.8) | RT-PCR |
Kute et al. [25] | 40 y/o | 1 | 0 | 0 | 0 | 0 | NC | ILI |
Leung et al. [26] | N/A | 64 | 0 | 0 | 141 | 12 | 8.5 (3.9, 13.1) | RT-PCR |
Lisena et al. [27] | Not specified | 5 | 0 | 0 | 1 | 1 | 100 (NC) | RT-PCR |
Maltezou et al. [28] | Median 11 days (0–27 days) | 13 | 0 | 0 | 0 | 0 | NC | ILI |
Morgan et al. [29] | N/A | 92 | 18 | 19.6 (11.5, 27.7) | 143 | 12 | 8.4 (3.8, 12.9) | ARI/ILI/RT-PCR |
Pannaraj et al. [30] | 2–343 d/o | 21 | 0 | 0 | 0 | 0 | NC | ILI |
Tsagris et al. [31] | Below 1 y/o | 20 | 1 | 5.0 (0, 14.6) | 0 | 0 | NC | RT-PCR |
van Gemert et al. [32] | 1–74 y/o | 57 | 1 | 1.8 (0, 5.2) | 65 | 17 | 26.2 (15.5, 36.8) | ILI |
Weston et al. [33] | N/A | 83 | 2 | 2.4 (0, 5.7) | 0 | 0 | NC | Non Specified |